Johan Vingerhoets

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial

José Valdez Madruga, Pedro Cahn, Beatriz Grinsztejn et al. · The Lancet · 2007 · 516 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +11

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial

Adriano Lazzarin, Thomas Campbell, Bonaventura Clotet et al. · The Lancet · 2007 · 392 citations

Medicine, Infectious Diseases, Pharmacology +12

TMC125, a Novel Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor Active against Nonnucleoside Reverse Transcriptase Inhibitor-Resistant Human Immunodeficiency Virus Type 1

Koen Andries, Hilde Azijn, Theo Thielemans et al. · Antimicrobial Agents and Chemotherapy · 2004 · 322 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +17

TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1

Hilde Azijn, Ilse Tirry, Johan Vingerhoets et al. · Antimicrobial Agents and Chemotherapy · 2009 · 294 citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +17

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S

Jerald Sadoff, Glenda Gray, An Vandebosch et al. · New England Journal of Medicine · 2022 · 250 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +12